Banque Pictet & Cie SA Sells 28,256 Shares of DexCom, Inc. (NASDAQ:DXCM)

Banque Pictet & Cie SA lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,553 shares of the medical device company's stock after selling 28,256 shares during the quarter. Banque Pictet & Cie SA's holdings in DexCom were worth $7,072,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of DXCM. Brighton Jones LLC boosted its stake in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after buying an additional 11,946 shares during the period. Bank Pictet & Cie Europe AG increased its stake in shares of DexCom by 1.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares in the last quarter. Atria Investments Inc increased its stake in shares of DexCom by 13.4% during the 4th quarter. Atria Investments Inc now owns 17,379 shares of the medical device company's stock worth $1,352,000 after purchasing an additional 2,059 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of DexCom during the 4th quarter worth approximately $5,812,000. Finally, Callan Family Office LLC purchased a new stake in DexCom in the 4th quarter worth approximately $238,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on DXCM. Robert W. Baird lowered their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Barclays lifted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $98.50.

DexCom Stock Performance

NASDAQ DXCM traded down $1.88 during trading hours on Friday, reaching $83.58. The company's stock had a trading volume of 976,560 shares, compared to its average volume of 4,410,438. The business has a 50-day simple moving average of $84.31 and a 200 day simple moving average of $79.97. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.19. The stock has a market cap of $32.77 billion, a PE ratio of 62.34, a PEG ratio of 1.81 and a beta of 1.44. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business earned $0.32 EPS. DexCom's revenue was up 12.5% compared to the same quarter last year. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president directly owned 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.